Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
manbetx3.0 的生物科技集团今年的目标是在风险投资、首次公开发行(IPO)以及与海外制药公司的许可交易中募集约100亿美元，这部分是因为确信manbetx3.0 研发的药物可以参与manbetx app苹果 竞争。
您已阅读4%（330字），剩余96%（7456字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。